These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25903947)

  • 1. Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin.
    Han YM; Park JM; Kangwan N; Jeong M; Lee S; Cho JY; Ko WJ; Hahm KB
    J Physiol Pharmacol; 2015 Apr; 66(2):159-67. PubMed ID: 25903947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of
    Sundaresan S; Kang AJ; Hayes MM; Choi EK; Merchant JL
    Gut; 2017 Jun; 66(6):1012-1021. PubMed ID: 26860771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.
    Han YM; Hahm KB; Park JM; Hong SP; Kim EH
    Neoplasia; 2014 Jan; 16(1):73-83. PubMed ID: 24563620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
    Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
    Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.
    Chueca E; Lanas A; Piazuelo E
    World J Gastroenterol; 2012 Dec; 18(45):6560-70. PubMed ID: 23236230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.
    Lee Y; Urbanska AM; Hayakawa Y; Wang H; Au AS; Luna AM; Chang W; Jin G; Bhagat G; Abrams JA; Friedman RA; Varro A; Wang KK; Boyce M; Rustgi AK; Sepulveda AR; Quante M; Wang TC
    Oncotarget; 2017 Jan; 8(1):203-214. PubMed ID: 27448962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
    Waldum HL; Sørdal Ø; Fossmark R
    Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems Associated with Deprescribing of Proton Pump Inhibitors.
    Helgadottir H; Bjornsson ES
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia and promotes gastric cancer cell survival.
    Vange P; Bruland T; Doseth B; Fossmark R; Sousa MML; Beisvag V; Sørdal Ø; Qvigstad G; Waldum HL; Sandvik AK; Bakke I
    PLoS One; 2017; 12(9):e0184514. PubMed ID: 28902909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric carcinoids after long-term use of a proton pump inhibitor.
    Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
    Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
    McCarthy DM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
    Lee L; Ramos-Alvarez I; Ito T; Jensen RT
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Proton Pump Inhibitors on Colorectal Cancer.
    Sasaki T; Mori S; Kishi S; Fujiwara-Tani R; Ohmori H; Nishiguchi Y; Hojo Y; Kawahara I; Nakashima C; Fujii K; Luo Y; Kuniyasu H
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors as also inhibitors of atrial fibrillation.
    Lin K; Chen X; Zhang L; Wang Y; Shan Z
    Eur J Pharmacol; 2013 Oct; 718(1-3):435-40. PubMed ID: 23973848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?
    Waldum HL; Hauso Ø; Brenna E; Qvigstad G; Fossmark R
    Scand J Gastroenterol; 2016 Jul; 51(7):767-73. PubMed ID: 26872579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
    Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
    Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
    Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
    Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
    Savarino V; Di Mario F; Scarpignato C
    Pharmacol Res; 2009 Mar; 59(3):135-53. PubMed ID: 18977444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway.
    Huang S; Chen M; Ding X; Zhang X; Zou X
    Int Immunopharmacol; 2013 Nov; 17(3):585-92. PubMed ID: 23973653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHRONIC USE OF PROTON PUMP INHIBITORS AND THE QUANTITY OF G, D, AND ECL CELLS IN THE STOMACH.
    Camilo SMP; Almeida ÉCS; Sousa JB; Camilo LP; Etchebehere RM
    Arq Bras Cir Dig; 2020; 33(2):e1506. PubMed ID: 32844883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.